Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer
Future Oncology · 01.06.2023 · 19 (19) · 1367-1378
DOI: 10.2217/fon-2023-0076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, online erschienen am 28.04.2023. Verfasst von Fengchun Mu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jin…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Clinical Research Special Fund of Wu Jieping Medical Foundation, National Natural Science Foundation of China, Start-up fund of Shandong Cancer Hospital.
Abstract (Originalsprache)
Background
The present study evaluated the efficacy and safety of nab-paclitaxel (nab-PTX) with a concurrent PD-1/PD-L1 inhibitor in patients with refractory relapsed small-cell lung cancer (SCLC). Patients & methods: We retrospectively analyzed 240 patients with refractory relapsed SCLC: 40 patients were treated with nab-PTX plus PD-1/PD-L1 inhibitor, and 200 received traditional chemotherapy.
Results
Median progression-free survival in the nab-PTX plus PD-1/PD-L1 inhibitor and traditional chemotherapy groups was 3.6 and 2.5 months (p = 0.0021), respectively. The median overall survival was 8.0 and 5.2 months (p = 0.0002), respectively. No new safety issues were identified.
Conclusion
Nab-PTX plus PD-1/PD-L1 inhibitor significantly improved survival in patients with refractory relapsed SCLC compared with traditional chemotherapy. Most patients with refractory relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival rates. This study analyzed the clinical outcomes and safety profiles of patients treated with nab-paclitaxel (nab-PTX) plus PD-1/PD-L1 inhibitor compared with patients treated with conventional chemotherapy. Notably, treatment with nab-paclitaxel and PD-1/PD-L1 inhibitor was associated with more favorable clinical outcomes, including better overall response and disease control rates, as well as longer overall survival and progression-free survival. In terms of side effect profiles, the two groups were balanced and had a similar incidence of grade ≥3 adverse events, including depleted blood cells and hair loss. To the best of our knowledge, we are the first to report the use of nab-PTX plus PD-1/PD-L1 inhibitor in the treatment of refractory relapsed SCLC. In addition, nab-PTX plus PD-1/PD-L1 inhibitor showed more effective antitumor activity in patients with secondary tumors in the liver, further confirming that nab-PTX plus PD-1/PD-L1 inhibitor is effective for patients with refractory relapsed SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
ORCID-Profile: Linlin Wang
Förderung
- Clinical Research Special Fund of Wu Jieping Medical Foundation
- National Natural Science Foundation of China
- Start-up fund of Shandong Cancer Hospital
Zitieren
APA
Mu, F., Fan, B., Li, H., Qin, W., Wang, C., Zou, B., & Wang, L. (2023). Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer. Future Oncology, 19(19), 1367-1378. https://doi.org/10.2217/fon-2023-0076
Vancouver
Mu F, Fan B, Li H, Qin W, Wang C, Zou B, et al. Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer. Future Oncology. 2023;19(19):1367-1378. doi:10.2217/fon-2023-0076
BibTeX
@article{Mu2023,
author = {Mu, Fengchun and Fan, Bingjie and Li, Haoqian and Qin, Wenru and Wang, Chunni and Zou, Bing and Wang, Linlin},
title = {Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {19},
pages = {1367--1378},
doi = {10.2217/fon-2023-0076}
}
EUVIMED